Liposome-based drug co-delivery systems in cancer cells

被引：239
作者：
Vahed, Sepideh Zununi [1 ]
Salehi, Roya [1 ,2 ]
Davaran, Soodabeh [1 ,2 ]
Sharifi, Simin [2 ,3 ]
机构：
[1] Tabriz Univ Med Sci, Chron Kidney Dis Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut Biotechnol, Tabriz, Iran
来源：
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS | 2017年 / 71卷
关键词：
Liposome; Co-delivery; Combination therapy; Chemotherapy; Cancer treatment; VASCULOGENIC MIMICRY CHANNELS; LARGE UNILAMELLAR VESICLES; SOLID LIPID NANOPARTICLES; EFFECTS IN-VITRO; BREAST-CANCER; ANTICANCER DRUG; VITAMIN-C; TRANSFERRIN RECEPTOR; MULTIDRUG-RESISTANCE; TARGETED LIPOSOMES;
D O I：
10.1016/j.msec.2016.11.073
中图分类号：
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号：
0805 ; 080501 ; 080502 ;
摘要：
Combination therapy and nanotechnology offer a promising therapeutic method in cancer treatment. By improving drug's pharmacoldnetics, nanoparticulate systems increase the drug's therapeutic effects while decreasing its adverse side effects related to high dosage. Liposomes are extensively used as drug delivery systems and several liposomal nanomedicines have been approved for clinical applications. In this regard, liposome-based combination chemotherapy (LCC) opens a novel avenue in drug delivery research and has increasingly become a significant approach in clinical cancer treatment This review paper focuses on LCC strategies including co-delivery of: two chemotherapeutic drugs, chemotherapeutic agent with anti-cancer metals, and chemotherapeutic agent with gene agents and ligand-targeted liposome for co-delivery of chemotherapeutic agents. Definitely, the multidisciplinary method may help improve the efficacy of cancer therapy. An extensive literature review was performed mainly using PubMed. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码：1327 / 1341
页数：15
相关论文
共 237 条
[11]  
Armat M, 2016, BOSNIAN J BASIC MED, V16, P28, DOI 10.17305/bjbms.2016.674
[12]  
Arredondo Miguel, 2005, Molecular Aspects of Medicine, V26, P313, DOI 10.1016/j.mam.2005.07.010
[13]   Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment [J].
Assanhou, Assogba G. ;
Li, Wenyuan ;
Zhang, Lei ;
Xue, Lingjing ;
Kong, Lingyi ;
Sun, Hongbin ;
Mo, Ran ;
Zhang, Can .
BIOMATERIALS, 2015, 73 :284-295
[14]   Treatment of cancer patients in their last month of life: aimless chemotherapy [J].
Assi, Tarek ;
El Rassy, Elie ;
Tabchi, Samer ;
Ibrahim, Toni ;
Moussa, Tania ;
Chebib, Ralph ;
El Karak, Fadi ;
Farhat, Fadi ;
Chahine, Georges ;
Nasr, Fadi ;
Ghosn, Marwan ;
Kattan, Joseph .
SUPPORTIVE CARE IN CANCER, 2016, 24 (04) :1603-1608
[15]  
Bakhshaiesh Tayebeh Oghabi, 2015, Asian Pac J Cancer Prev, V16, P5191
[16]   The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles [J].
Bao, Quan-Ying ;
Zhang, Ning ;
Geng, Dong-Dong ;
Xue, Jing-Wei ;
Merritt, Mackenzie ;
Zhang, Can ;
Ding, Ya .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 477 (1-2) :408-415
[17]   Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors [J].
Batist, Gerald ;
Gelmon, Karen A. ;
Chi, Kim N. ;
Miller, Wilson H., Jr. ;
Chia, Stephen K. L. ;
Mayer, Lawrence D. ;
Swenson, Christine E. ;
Janoff, Andrew S. ;
Louie, Arthur C. .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :692-700
[18]   Systematic discovery of multicomponent therapeutics [J].
Borisy, AA ;
Elliott, PJ ;
Hurst, NW ;
Lee, MS ;
Lehár, J ;
Price, ER ;
Serbedzija, G ;
Zimmermann, GR ;
Foley, MA ;
Stockwell, BR ;
Keith, CT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) :7977-7982
[19]   Liposomes as nanomedical devices [J].
Bozzuto, Giuseppina ;
Molinari, Agnese .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10 :975-999
[20]  
Bradbury R, 2016, ANTICANCER RES, V36, P1143
12345678910